Barclays analyst Stephanie Davis reiterated an Overweight rating and $39.00 price target on Evolent Health (NYSE: EVH)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE